<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 14, 2020 (HealthDay News) — Sitagliptin treatment added to standard care is associated with reduced mortality and improved clinical outcomes for patients with type 2 diabetes hospitalized with COVID-19, according to a study published online Sept. 29 in Diabetes Care<\/i>.<\/p>\n
Sebastiano Bruno Solerte, from the University of Pavia in Italy, and colleagues conducted a multicenter, case-control, retrospective, observational study involving patients with type 2 diabetes hospitalized with COVID-19; patients had pneumonia and exhibited oxygen saturation <95 percent when breathing ambient air or when receiving oxygen support. Patients received sitagliptin added to standard of care (169 patients) or standard of care alone (169 patients).<\/p>\n
The researchers found that compared with patients receiving standard of care alone, treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18 versus 37 percent; hazard ratio, 0.44), an improvement in clinical outcomes (60 versus 38 percent), and a greater number of hospital discharges (120 versus 89 discharged patients).<\/p>\n
“Given the beneficial effects observed in lowering mortality rate and improving clinical outcomes, sitagliptin may also be considered for further testing in patients with COVID-19 and without type 2 diabetes,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n